Recent Insider Transactions • Jul 02
Key Executive recently sold €773k worth of stock On the 26th of June, Michael Köhler sold around 12k shares on-market at roughly €64.40 per share. This transaction amounted to 4.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months. お知らせ • Apr 17
Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026 Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller. Breakeven Date Change • Mar 05
Forecast breakeven date pushed back to 2027 The 8 analysts covering Redcare Pharmacy previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 92% to 2026. The company is expected to make a profit of €38.0m in 2027. Average annual earnings growth of 55% is required to achieve expected profit on schedule. お知らせ • Feb 07
Redcare Pharmacy NV to Report Q2, 2026 Results on Jul 29, 2026 Redcare Pharmacy NV announced that they will report Q2, 2026 results on Jul 29, 2026 お知らせ • Jan 28
Redcare Pharmacy N.V. Supports Seamless Continuation Of Digital E-Prescription Journey With PoPP Draft Specifications Redcare Pharmacy N.V. reported that the national agency responsible for the digitalization of the healthcare system in Germany (gematik) has published the draft specifications of the PoPP (Proof of Patient Presence) module for remote care use case, including the digital redemption of e-prescriptions. PoPP is intended to replace the current VSDM++ patient card verification process on which Redcare’s CardLink solution is based. In its current draft form, the PoPP specifications confirm the continuation of a smooth, low-threshold digital process for e-prescription redemption using Redcare’s Shop Apotheke app in Germany. The ability to verify the eGK and a patient’s insured status without PIN on the app can continue now even more effectively, since an SMS for mobile number verification will no longer be required. Combined with the added optionality of using a digital ID in the future, this ensures stability, more flexibility and supports the continued adoption of digital solutions. The migration to PoPP is part of a broader modernization of Germany’s telematics infrastructure. The new technology raises security standards for data protection while enabling more flexible, software-based authentication options. Beyond enhanced security, this approach is expected to improve accessibility to healthcare services, particularly in remote and digital care settings. Following the publication of the final PoPP specifications for the remote care use case – anticipated in the First Quarter 2026 – Redcare Pharmacy will finalize the technical implementation within its Shop Apotheke app and secure the required regulatory approvals. The official rollout of PoPP Stufe 2 – Online Check-in by gematik is currently planned for the end of 2026. Redcare Pharmacy’s CardLink license extension remains valid until January 31, 2027, providing ample runway for a smooth and well-managed transition. お知らせ • Jan 08
Redcare Pharmacy NV to Report Fiscal Year 2025 Final Results on Mar 04, 2026 Redcare Pharmacy NV announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Mar 04, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: €719.2m (up 25% from 3Q 2024). Net loss: €7.24m (loss widened 4.8% from 3Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Consumer Retailing industry in Europe. New Risk • Oct 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Significant insider selling over the past 3 months (€307k sold). お知らせ • Oct 07
Redcare Pharmacy NV to Report Q3, 2025 Results on Oct 29, 2025 Redcare Pharmacy NV announced that they will report Q3, 2025 results on Oct 29, 2025 お知らせ • Sep 28
Redcare Pharmacy NV Announces Stepping Down of Jasper Eenhorst from the Management Board Redcare Pharmacy NV announced that Jasper Eenhorst will stepping down from the Managing Board, but will remain with the company until the end of this year to support a smooth transition to his successor. Reported Earnings • Jul 29
Second quarter 2025 earnings released: EPS: €0.46 (vs €0.21 loss in 2Q 2024) Second quarter 2025 results: EPS: €0.46 (up from €0.21 loss in 2Q 2024). Revenue: €709.2m (up 27% from 2Q 2024). Net income: €9.35m (up €13.6m from 2Q 2024). Profit margin: 1.3% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. お知らせ • Mar 19
Redcare Pharmacy NV to Report Q2, 2025 Results on Jul 29, 2025 Redcare Pharmacy NV announced that they will report Q2, 2025 results on Jul 29, 2025 お知らせ • Jul 30
Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG. Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG on mid-May last year.
Redcare Pharmacy NV (XTRA:RDC) completed the acquisition of MediService AG on mid-May last year.